These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 39101502)

  • 1. DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras.
    Li F; Hu Q; Zhou Y; Yang H; Bai F
    Brief Bioinform; 2024 Jul; 25(5):. PubMed ID: 39101502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs.
    Li F; Hu Q; Zhang X; Sun R; Liu Z; Wu S; Tian S; Ma X; Dai Z; Yang X; Gao S; Bai F
    Nat Commun; 2022 Nov; 13(1):7133. PubMed ID: 36414666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROTACable Is an Integrative Computational Pipeline of 3-D Modeling and Deep Learning To Automate the De Novo Design of PROTACs.
    Mslati H; Gentile F; Pandey M; Ban F; Cherkasov A
    J Chem Inf Model; 2024 Apr; 64(8):3034-3046. PubMed ID: 38504115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D based generative PROTAC linker design with reinforcement learning.
    Li B; Ran T; Chen H
    Brief Bioinform; 2023 Sep; 24(5):. PubMed ID: 37670499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
    Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
    Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nano-PROTACs: state of the art and perspectives.
    Zhong J; Zhao R; Wang Y; Su YX; Lan X
    Nanoscale; 2024 Feb; 16(9):4378-4391. PubMed ID: 38305466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
    Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
    Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes.
    Zaidman D; Prilusky J; London N
    J Chem Inf Model; 2020 Oct; 60(10):4894-4903. PubMed ID: 32976709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
    Tamatam R; Shin D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current strategies for the design of PROTAC linkers: a critical review.
    Troup RI; Fallan C; Baud MGJ
    Explor Target Antitumor Ther; 2020; 1(5):273-312. PubMed ID: 36046485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs).
    Abbas A; Ye F
    Int J Biol Macromol; 2024 Oct; 277(Pt 4):134293. PubMed ID: 39084437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection.
    Zahid S; Ali Y; Rashid S
    J Biomol Struct Dyn; 2023; 41(23):14566-14581. PubMed ID: 36841549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 19. Elucidation of Genome-wide Understudied Proteins targeted by PROTAC-induced degradation using Interpretable Machine Learning.
    Xie L; Xie L
    bioRxiv; 2023 Feb; ():. PubMed ID: 36865212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor.
    Apprato G; D'Agostini G; Rossetti P; Ermondi G; Caron G
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.